Eli Lilly is set to launch a new pragmatic study of its drug candidate, bamlanivimab (LY-CoV555) in high-risk patients with COVID-19 in New Mexico.
Bamlanivimab is a recombinant, neutralising human IgG1 monoclonal antibody directed against the spike protein of SARS-CoV-2, developed by Lilly and AbCellera.
“It is important to continue building on the evidence base for bamlanivimab through ongoing studies, including those in a real-world setting. In addition to gathering treatment and safety data, Lilly will use this study to explore the delivery of bamlanivimab in a variety of innovative infusion settings, which could help inform best practices and ultimately replication by institutions around the country.” said Eli Lilly’s chief scientific officer and Research Laboratories president Daniel Skovronsky.
The study will analyse the effectiveness of bamlanivimab in reducing COVID-19 hospitalisations in high-risk group.Lilly will use its mobile research units which have a custom retrofitted recreational vehicle (RV) solution to support mobile labs and clinical trial material preparation.In September, Lilly reported positive proof-of-concept results from the BLAZE-1 clinical trial, which assessed SARS-CoV-2 neutralising antibody candidate LY-CoV555, to treat symptomatic COVID-19 in outpatients.